Salix Pharmaceuticals — Inkine Pharmaceutical — Merger or Acquisition (July 2005)
44 slides from Salix Pharmaceuticals's merger presentation, Jul 28, 2005
Slide 1: Salix Pharmaceuticals, Ltd. The Gastroenterology Company
Salix Pharmaceuticals, Ltd. The Gastroenterology Company
Slide 2: Merger legal notice: S-4 and proxy solicitation
In connection with the merger between Salix and InKine, on July 18, 2005 Salix filed with the SEC a registration statement on Form S-4, containing a preliminary joint proxy statement/prospectus and other relevant materials. INVESTORS AND SECURITY HOLDERS OF SALIX AND INKINE ARE URGED TO READ THE DEF
Slide 3: Forward Looking Statement
FORWARD LOOKING STATEMENT Statements presented in this overview which are not historical facts are forward looking statements that involve risks and uncertainties that could cause actual results to differ from projected results. Factors that could cause actual results to differ materially include th
Slide 4: Mission Statement
MISSION STATEMENT Salix Pharmaceuticals is dedicated to being the leading specialty pharmaceutical company providing products to gastroenterologists and their patients Salix Pharmaceuticals, Ltd.
Slide 5: Strategy
STRATEGY Maximize shareholder value: In-license selective late-stage/marketed product candidates U.S. gastroenterology focus Reduce risk and capital commitment Complete development and secure FDA approval Sell products through specialty sales force Establish franchise with U.S. gastroenterologists S
Slide 6: Combined Pipeline
COMBINED PIPELINE Product Indication Sales Preclinical Phase I Phase 2 Phase 3 NDA Marketed COLAZAL Ulcerative Colitis $85.4 VISICOL Colon Cleansing prior to colonoscopy 20.5 XIFAXAN Antibiotic for travelers’ diarrhea 9.8 ANUSOL / PROCTOCORT Itching / Inflammation 4.6 AZASAN Rheumatoid Arthritis, UC
Slide 7: Salix Pharmaceuticals, Ltd. The Gastroenterology Company
Salix Pharmaceuticals, Ltd. The Gastroenterology Company Providing products to gastroenterologists and their patients
Slide 8: A. Asher Kornbluth, MD
A. Asher Kornbluth, MD Associate Clinical Professor of Medicine Mount Sinai School of Medicine
Slide 9: Rifaximin (XIFAXAN)
Rifaximin (XIFAXAN™) Virtually non-absorbable semisynthetic antibiotic Related to Rifamycin Resistance not plasmid-mediated but a chromosomal one-step alteration in the DNA-dependent RNA polymerase Rifamycin Rifaximin Antimicrobial spectrum includes Most gram-positive and gram-negative bacteria Both
Slide 10: Rifaximin (XIFAXAN) Profile
Rifaximin (XIFAXAN™) Profile Nonabsorbed (<0.4%) Broad-spectrum antibacterial activity Tolerability profile comparable to placebo No known drug interactions No clinically relevant bacterial resistance observed Fecal levels achieved during rifaximin therapy exceed the MIC90 by 250 times
Slide 11: Published Therapeutic Uses
Published Therapeutic Uses Pouchitis Prophylaxis for GI surgery Small bowel overgrowth Travelers’ diarrhea Therapy and prophylaxis Ulcerative colitis Clostridium difficile- associated diarrhea Crohn’s disease Diverticular disease Hepatic encephalopathy Helicobacter pylori eradication Infectious diar
Slide 12: Availability and years of use outside the United States
Availability 18 years of use outside the United States Approved in 18 countries worldwide Over 500 million tablets distributed Approved in the United States in May 2004 More than 2500 patients assessed in United States clinical studies
Slide 13: U.S. Indication
U.S. Indication XIFAXAN tablets are indicated for the treatment of patients (>12 years of age) with travelers’ diarrhea caused by noninvasive strains of Escherichia coli Dosage: 200mg TID for 3 days
Slide 14: Ongoing Clinical Activities
Ongoing Clinical Activities Travelers’ diarrhea therapy Travelers’ diarrhea prophylaxis Pediatric Infectious Diarrhea Hepatic encephalopathy Crohn’s disease Pouchitis Clostridium difficile- associated diarrhea Irritable bowel syndrome Food/waterborne bioterrorism
Slide 15: Rationale for XIFAXAN in Active Crohn's Disease
Rationale for XIFAXAN in Active Crohn’s Disease CD is a chronic inflammatory disorder Growing evidence that normal enteric bacteria may contribute to chronic pathologic inflammatory responses Randomized controlled trials have demonstrated that antibiotics have a beneficial effect on CD XIFAXAN may b
Slide 16: XIFAXAN in Active Crohn's Disease
XIFAXAN in Active Crohn’s Disease Preliminary open-label study 29 patients Symptoms for at least 3 months before screening CDAI score >220 and <400 XIFAXAN given at a dose of 200 mg TID for 16 weeks Primary endpoint Mean change in CDAI score from baseline to month 4 Secondary endpoint Percentage of
Slide 17: Improvement in CDAI Score and Remission Rates
Improvement in CDAI Score and Remission Rates 82% 82% 78% 59% 59% 56% 56% % of Patients 41% Month 3 Month 2 Month 1 Month 4 Shafran I, et al. Am J Gastroenterol. 2003;98(9 suppl):S250.
Slide 18: XIFAXAN Safety & Efficacy in Mild-Moderate Crohn's Disease
XIFAXAN Safety & Efficacy in Mild — Moderate Crohn’s Disease 30 patients with mild — moderate disease Despite standard therapies 5-ASA Budesonide Antibiotics: metronidazole; ciprofloxacin Prednisone 6-MP XIFAXAN dose: 400 mg BID in 20 patients 200 mg TID in 10 patients Mean age = 42 (15-69) Mean dur
Slide 19: Clinical Improvement with XIFAXAN
Clinical Improvement with XIFAXAN 70% 67% 63% 60% 50% 47% % Improvement 40% 30% 20% 10% 0% Ileocolitis Ileitis Colitis Kornbluth A. Abstract W1029. DDW 2005.
Slide 20: Results
Results Mean time to onset of efficacy 2.4 weeks (range 1-9 weeks) All 16 patients with clinical response chose to continue XIFAXAN Steroid Sparing: 3 of 6 patients on baseline prednisone reduced their dose by a mean of 50% 3 of 7 patients on baseline budesonide reduced their dose by 44% Benefit mos
Slide 21: XIFAXAN in Moderate-Severe Refractory Crohn's
XIFAXAN in Moderate - Severe Refractory Crohn’s Preliminary open-label study 8 patients Refractory to conventional therapy Mean age: 43.8 Mean Harvey Bradshaw Index: 10.9 XIFAXAN given at a dose of 400 mg BID for at least 10 days Treatment ranged from 10 days to 5 months Primary endpoint Change in d
Slide 22: Significant Decrease in Harvey Bradshaw Index with XIFAXAN
Significant Decrease in Harvey Bradshaw Index with XIFAXAN Harvey Bradshaw Index Pre-Rifaximin Post-Rifaximin Mean improvement of 63.1% Median time to response 7 days Duration of therapy 31 days (median) Bosworth B, et al. Abstract W1013. DDW 2005.
Slide 23: XIFAXAN Efficacy in Small Bowel Bacterial Overgrowth
XIFAXAN Efficacy in Small Bowel Bacterial Overgrowth (SBBO) N= 14 SBBO documented with a positive lactulose breath test XIFAXAN 400 mg po BID x 14 days Pts were evaluated and assessed for Response (None, < 50%, >50%, Complete Remission) Time to onset of efficacy AEs Response to prior meds Previous a
Slide 24: Clinical Response with XIFAXAN
Clinical Response with XIFAXAN 100% 93% (13 of 14) Response Mean Time to Onset of Response - 4 days (range: 1-16 days) Complete Response 10 days (range: 3-21 days). 92% (12 of 13) Complete Remission 8% reported > 50% response 92% n=13* 90% 80% 70% 60% 50% 40% 30% 20% 8% 0% 10% Complete Remission > 5
Slide 25: Results
Results Mean bowel frequency decreased from 9 to 2 / day All pts (13/13) reported decreased fecal urgency and complete resolution of abdominal pain No AEs occurred in any pts Underlying diagnoses were: CD (n=10; 1 did not respond), Scleroderma (n=2), Mixed Connective Tissue Disorder (n=2) Baidoo L,
Slide 26: XIFAXAN Efficacy in Pouchitis
XIFAXAN Efficacy in Pouchitis N= 10 Prospectively evaluated based on classic symptoms of pouchitis All pts had current (n=6) or recent (n=4) endoscopies of pouch consistent w/pouchitis XIFAXAN 400 mg po BID x 14 days Pts were evaluated and assessed for: Response (None, < 50%, >50%, Complete Remissio
Slide 27: Clinical Response with XIFAXAN
Clinical Response with XIFAXAN 90% (9 of 10) Response Mean Time to Onset of Response - 3 days (range: 1-7 days) Complete Response - - 7 days (range: 2-12 days). 89% (8 of 9) Complete Remission 11% reported > 50% response 100% n=9* 89% 90% 80% 70% 60% 50% 40% 30% 11% 20% 10% 0% > 50% response Complet
Slide 28: Results
Results The mean bowel frequency decreased from 14 to 5/day All pts also reported decreased fecal urgency and complete resolution of abdominal pain No AEs were noted in any pts 3 pts who had remission had been refractory to ciprofloxacin 500 mg po BID Baidoo L, et al. Abstract M1975. DDW 2005
Slide 29: Conclusions
Conclusions XIFAXAN may have a therapeutic role in: Active Crohn’s disease Maintenance of remission Prevention of postsurgical relapse SBBO and IBS Pouchitis Clostridium difficile associated colitis
Slide 30: Carroll B. Leevy, MD
Carroll B. Leevy, MD Associate Professor of Medicine and Associate Director for Clinical Affairs New Jersey Medical School Liver Center and Sammy Davis, Jr. National Liver Institute
Slide 31: Treatment of Hepatic Encephalopathy: The Role of Antibiotics and XIFAXAN
Treatment of Hepatic Encephalopathy: The Role of Antibiotics and XIFAXAN™
Slide 32: Overview of Hepatic Encephalopathy (HE)
Overview of Hepatic Encephalopathy (HE) Encompasses a wide spectrum of reversible neuropsychiatric abnormalities Characterized by: Disturbances in consciousness Changes in personality and intellectual capacity High blood ammonia (NH3) levels Altered neuromuscular activity Electroencephalogram (EEG)
Slide 33: Potential Impact of HE
Potential Impact of HE Estimated prevalence of chronic liver disease and cirrhosis in the U.S. is 5.5 million cases Most common causes are hepatitis B, hepatitis C, and alcoholism ~20%-60% of patients with liver disease experience minimal HE ~10%-50% of patients with portocaval shunts may experience
Slide 34: Potential Impact of HE (cont.)
Potential Impact of HE (cont.) True incidence and prevalence of HE is difficult to establish In 2002, there were over 50,000 hospitalizations attributed to HE In 2004, there were 197,000 doctor visits for HE Prognosis after developing overt HE is poor 1-year survival estimated at 42% 3-year survival
Slide 35: Properties of an Antibiotic Useful for HE
Properties of an Antibiotic Useful for HE Provides broad spectrum coverage against both aerobic and anaerobic bacteria Effectively controls neuropsychiatric signs and symptoms Is extremely well tolerated and safe in the target population, which is characterized by compromised gastrointestinal, bilia
Slide 36: Published Studies of XIFAXAN in HE
Published Studies of XIFAXAN in HE Open label (3) Dose finding (1) Comparative, randomized, controlled trials (12) XIFAXAN vs lactulose (4) XIFAXAN vs lactitol (1) XIFAXAN vs paromomycin (3) XIFAXAN vs neomycin (4) Placebo-controlled trial (1)
Slide 37: Rifaximin vs Lactitol: Patients With Grades I-III HE
Rifaximin vs Lactitol: Patients With Grades I–III HE Randomized, double-blind study of 103 patients: 30% grade I 49% grade II 21% grade III Treatment groups: Rifaximin 400 mg TID (n=50) Lactitol 20 g TID (n=53) Treatment period: 5 to 10 days Evaluation based on changes in PSE index at end of study M
Slide 38: Rifaximin vs Lactitol (cont'd)
Rifaximin vs Lactitol: Patients With Grades I–III HE (cont’d) Changes in HE and PSE Index Rifaximin 1200 mg/d (n=50) Lactitol 60 g/d (n=53) Entry End Entry End P Value* Blood Ammonia (g/dL) 0.008 Mean PSE index 0.61 0.14 0.55 0.21 0.010 Mean improvement in HE (%) 70.0 61.5 0.008 * Two-tailed P value
Slide 39: XIFAXAN vs Lactulose
XIFAXAN vs Lactulose: Randomized, Double-Blind Study 40 cirrhotic patients with grades I to III HE Treatment groups: XIFAXAN 1200 mg/day (n = 20) Lactulose 60 g/day (n = 20) Treatment period: 15 days Evaluations included blood ammonia, mental state, asterixis, EEG abnormalities, HE score Massa P, et
Slide 40: XIFAXAN vs Lactulose: Results
XIFAXAN vs Lactulose: Randomized, Double-Blind Study, Results XIFAXAN significantly (p< 0.05 vs lactulose) improved: Blood ammonia levels on days 6 and 9 Mental state on day 12 Asterixis on day 6 EEG on days 6 and 9 HE score on days 6 and 15 Massa P, et al. Eur J Clin Res. 1993(4):7-18.
Slide 41: XIFAXAN vs Lactulose: Results
XIFAXAN vs Lactulose: Randomized, Double-Blind Study, Results XIFAXAN: no drug-related side effects reported Lactulose Nausea (n = 5) Anorexia (n = 7) Flatulence + diarrhea (n = 13) Cramps (n = 3) Massa P, et al. Eur J Clin Res. 1993(4):7-18.
Slide 42: XIFAXAN vs Neomycin
XIFAXAN vs Neomycin: Randomized, Double-Blind Study 30 cirrhotic patients with grade I to III HE Treatment groups: XIFAXAN 1200 mg/day (n = 15) Neomycin 3 g/day (n = 15) Treatment period: 21 days Primary endpoint: venous blood ammonia level Secondary endpoints: EEG grade, number-connection test time
Slide 43: XIFAXAN vs Neomycin: Results
XIFAXAN vs Neomycin: Randomized, Double-Blind Study, Results Number Connection Test Blood NH3 XIFAXAN 205.6 XIFAXAN Neomycin Neomycin 181.2 ‡ p<0.005 137.6 * µmol/L Seconds † 134.5 * 118.2 * 95.8 84.6 78.6 Day 0 Day 21 Day 0 Day 21 * p<0.001, posttreatment vs baseline levels † p<0.025, posttreatment
Slide 44: XIFAXAN in HE: Conclusions
XIFAXAN in HE: Conclusions The primary treatment goal of HE is to reduce the production and absorption of NH3 and other bacteria-generated toxins Rifaximin is as effective in controlling HE as lactulose, lactitol, and neomycin with faster response in blood NH3 and EEG Safety and tolerability of XIFA
Inkine Pharmaceutical — Merger or Acquisition (July 2005) on 6ix